logo-loader
viewMetVital

MetVital is raising $10 mln for its phase2A clinical trial to treat brain cancer

MetVital, Inc CEO Alan Cash sat down with Proactive at the BIO Investor Forum in San Francisco. 

The San Diego-based biopharmaceutical company is developing small molecule modulators of glutamate metabolism for the treatment of diseases like brain cancer.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Touchstone Exploration now has the 'certainty' to accelerate its Ortoire...

Touchstone Exploration Inc's (LON:TXP) (TSE:TXP) Paul Baay speaks to Proactive London's Andrew Scott after announcing they've raised US$11.6mln (£9mln) through a share placing. The new funds have been earmarked for the acceleration of its  exploration activities in the Ortoire block.

27 minutes ago

2 min read